DexCom, Inc.
DXCMLast close · Oct 16, 202686.04−1.67 (−1.90%)
Market cap$32.5B
12 firms' latest targets, last 90 days: median $96.00 ($90.00–$115.00), 12% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-13 | Mizuho Securities | $100.00 | ▲ 18% | +16% |
| 2026-10-06 | Barclays | $115.00 | ▲ 80% | +34% |
| 2026-10-01 | RBC Capital | $105.00 | ▲ 17% | +22% |
| 2026-09-18 | Truist | $102.00 | ▲ 10% | +19% |
| 2026-08-04 | Argus Research | $96.00 | — | +12% |
| 2026-08-03 | Canaccord Genuity | $90.00 | ▲ 10% | +5% |
| 2026-07-31 | Raymond James | $94.00 | ▲ 3% | +9% |
| 2026-07-31 | Piper Sandler | $95.00 | ▲ 8% | +10% |
| 2026-07-31 | Baird | $105.00 | ▲ 31% | +22% |
| 2026-07-31 | BTIG | $90.00 | — | +5% |
| 2026-07-31 | Stifel | $95.00 | ▲ 6% | +10% |
| 2026-07-28 | UBS | $96.00 | ▲ 1% | +12% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $3.6B | +24% | $1.30 | +59% | est. $3.6B+1% | est. $1.44 | 12 |
| 2024reported | $4.0B | +11% | $1.42 | +9% | est. $4.0B+0% | est. $1.67 | 16 |
| 2025reported | $4.7B | +16% | $2.09 | +47% | est. $4.7B+0% | est. $2.06 | 17 |
| 2026 | $5.2B | +12% | $2.67 | +30% | $5.2B–$5.3B | $2.48–$2.73 | 21 |
| 2027 | $5.8B | +11% | $3.13 | +17% | $5.7B–$5.9B | $2.87–$3.34 | 21 |
| 2028 | $6.5B | +11% | $3.73 | +19% | $6.2B–$6.6B | $2.95–$4.07 | 20 |
| 2029 | $7.2B | +11% | $4.31 | +15% | $7.0B–$7.3B | $4.20–$4.38 | 10 |
| 2030 | $7.9B | +11% | $5.02 | +16% | $7.8B–$8.0B | $4.90–$5.10 | 10 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.